株探米国株
英語
エドガーで原本を確認する

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one) 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2023

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission file number 000-05576

 

DOMINARI HOLDINGS INC.
(Exact name of registrant as specified in its charter)

 

Delaware   52-0849320
(State or other jurisdiction
of incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

725 5th Avenue, 22nd Floor, New York, NY 10022
(Address of Principal Executive Offices, including zip code)

 

(703) 992-9325
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files.) Yes ☒ No ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer Accelerated Filer
Non-accelerated Filer Smaller Reporting Company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   DOMH   The Nasdaq Capital Market LLC

 

As of August 8, 2023, there were 5,345,312 shares of the Company’s common stock issued and outstanding.

 

 

 

 


  

DOMINARI HOLDINGS INC.

Form 10-Q

For the Quarter Ended June 30, 2023

Index 

 

    Page No. 
     
Part I. Financial Information  
     
Item 1. Financial Statements (Unaudited) 1
     
  Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022 1
     
  Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022 (Unaudited) 2
     
  Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three and six months ended June 30, 2023 and 2022 (Unaudited) 3
     
  Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 (Unaudited) 5
     
  Notes to the Condensed Consolidated Financial Statements (Unaudited) 6
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
     
Item 4. Controls and Procedures 24
     
Part II. Other Information  
     
Item 1. Legal Proceedings 25
     
Item 1A. Risk Factors 25
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
     
Item 3. Defaults Upon Senior Securities 25
     
Item 4. Mine Safety Disclosures 25
     
Item 5. Other Information 25
     
Item 6. Exhibits 25
     
Signatures 26

 

i


  

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

DOMINARI HOLDINGS INC.

Condensed Consolidated Balance Sheets

($ in thousands except share and per share amounts)

 

    June 30,     December 31,  
    2023     2022  
    (Unaudited)        
ASSETS            
Current assets            
Cash and cash equivalents   $ 3,598     $ 33,174  
Marketable securities     20,675       7,130  
Deposits with clearing broker     7,082      
-
 
Prepaid expenses and other assets     715       564  
Prepaid acquisition cost    
-
      301  
Short-term investments, at fair value     13       13  
Notes receivable, at fair value - current portion     6,339       7,474  
Investment in Fieldpoint Securities    
-
      2,000  
Total current assets     38,422       50,656  
                 
Property and equipment, net     387      
-
 
Notes receivable, at fair value - non-current portion     1,622       1,100  
Employee forgivable loan receivable     98      
-
 
Investments     23,178       23,103  
Right-of-use assets     3,530       919  
Security deposit     458       458  
Total assets   $ 67,695     $ 76,236  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current liabilities                
Accounts payable and accrued expenses   $ 232     $ 447  
Accrued salaries and benefits     632       1,260  
Income taxes withheld     1,300      
-
 
Accrued Commissions     17      
-
 
Lease liability - current     353       82  
Other Current liability     124      
-
 
Total current liabilities     2,658       1,789  
                 
Lease liability     3,259       680  
Total liabilities     5,917       2,469  
                 
Stockholders’ equity                
Preferred stock, $.0001 par value, 50,000,000 Authorized    
 
     
 
 
Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding at June 30, 2023 and December 31, 2022; liquidation value of $0.0001 per share    
-
     
-
 
Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding at June 30, 2023 and December 31, 2022; liquidation value of $0.0001 per share    
-
     
-
 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 5,345,312 and 5,485,096 shares issued at June 30, 2023 and December 31, 2022, respectively; 5,285,164 and 5,017,079 shares outstanding at June 30, 2023 and December 31, 2022, respectively    
-
     
-
 
Additional paid-in capital     260,585       262,970  
Treasury stock, at cost, 60,148 and 468,017 shares at June 30, 2023 and December 31, 2022, respectively     (501 )     (3,322 )
Accumulated deficit     (198,306 )     (185,881 )
Total stockholders’ equity     61,778       73,767  
Total liabilities and stockholders’ equity   $ 67,695     $ 76,236  

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

1


 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Operations

($ in thousands except share and per share amounts)

(Unaudited)

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2023     2022     2023     2022  
Revenues   $ 71     $
-  
    $ 71     $
-  
 
                                 
Operating costs and expenses                                
General and administrative   $ 9,080     $ 2,262     $ 12,913     $ 4,049  
Research and development     2       36       3       2,052  
Total operating expenses     9,082       2,298       12,916       6,101  
Loss from operations     (9,011 )     (2,298 )     (12,845 )     (6,101 )
                                 
Other income (expenses)                                
Other income    
-  
     
-  
     
-  
      64  
Interest income     160       220       297       399  
Gain (loss) on marketable securities     400       (2,239 )     335       (2,736 )
Unrealized loss on note receivable     (212 )    
-  
      (212 )    
-  
 
Change in fair value of investments    
-  
      (760 )    
-  
      (238 )
Total other income  (expenses)     348       (2,779 )     420       (2,511 )
Net loss   $ (8,663 )   $ (5,077 )   $ (12,425 )   $ (8,612 )
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock    
-  
      (1,100 )    
-  
      (4,109 )
Net Loss Attributable to Common Shareholders   $ (8,663 )   $ (6,177 )   $ (12,425 )   $ (12,721 )
                                 
Net loss per share, basic and diluted                                
Basic and Diluted
  $ (1.79 )   $ (1.18 )   $ (2.45 )   $ (2.42 )
                                 
Weighted average number of shares outstanding, basic and diluted                                
Basic and Diluted
    4,827,239       5,251,023       5,065,055       5,251,766  

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

2


  

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity

($ in thousands except share and per share amounts)

(Unaudited)

 

For the Three Months Ended June 30, 2023 and 2022

 

    Preferred Stock     Common Stock     Additional
Paid-in
    Treasury Stock     Accumulated     Total
Stockholders’
 
    Shares     Amount     Shares     Amount     Capital     Shares     Amount     Deficit     Equity  
Balance at March 31, 2023     4,659     $      -       4,815,597     $        -     $ 259,215       60,148     $ (501 )   $ (189,643 )   $ 69,071  
Stock-based compensation    
-
     
-
      529,715      
-
      1,370      
-
     
-
     
-
      1,370  
Net loss     -      
-
      -      
-
      -       -      
-
      (8,663 )     (8,663 )
Balance at June 30, 2023     4,659     $
-
      5,345,312     $
-
    $ 260,585       60,148     $ (501 )   $ (198,306 )   $ 61,778

 

   

Redeemable Convertible

Preferred Stock

            Preferred     Additional                 Total  
    Series O     Series P       Common Stock     Stock     Paid-in     Treasury Stock     Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount       Shares     Amount     Shares     Amount     Capital     Shares     Amount     Deficit     Equity  
Balance at March 31, 2022     11,000     $ 11,000     11,000   $   11,000         5,252,517     $            -       4,659     $        -      $ 262,624       -     $ (264 )   $ (167,309 )   $    95,051  
Redemption of Series O Redeemable Convertible Preferred Stock     (11,000 )     (11,000 )     -       -         -       -       -       -       -       -       -       -       -  
Redemption of Series P Redeemable Convertible Preferred Stock     -       -       (11,000 )     (11,000 )     -       -       -       -       -       -       -       -       -  
Deemed dividends related to Series O and Series P  Redeemable Convertible Preferred Stock     -       -       -       -         -       -       -       -       (1,100 )     -       -       -       (1,100 )
Repurchase of treasury stock     -       -       -       -         -       -       -       -       -       242,902       (1,486 )    
 
      (1,486 )
Stock-based compensation     -       -       -       -         -       -       -       -       105       -       -       -       105  
Fractional shares adjusted for reverse split     -       -       -       -         (5,665 )     -       -       -       (26 )     -       -       -       (26 )
Net loss     -       -       -       -         -       -       -       -       -       -       -       (5,077 )     (5,077 )
Balance at June 30, 2022     -     $ -       -     $ -         5,246,852     $ -       4,659     $ -     $ 261,603       242,902     $ (1,750 )   $ (172,386 )   $ 87,467  

 

3


 

For the Six Months Ended June 30, 2023 and 2022

 

    Preferred Stock     Common Stock     Additional
Paid-in
    Treasury Stock     Accumulated     Total Stockholders’  
    Shares     Amount     Shares     Amount     Capital     Shares     Amount     Deficit     Equity  
Balance at December 31, 2022     4,659     $
        -
      5,485,096     $
         -
    $ 262,970       468,017     $ (3,322 )   $ (185,881 )   $ 73,767  
Stock-based compensation     -      
-
      529,715      
-
      1,375       -      
-
     
-
      1,375  
Cancellation of common stock     -      
-
      (25,000 )    
-
     
-
      -      
-
     
-
     
-
 
Purchase of treasury stock     -      
-
      -      
-
     
-
      236,630       (939 )    
-
      (939 )
Retirement of treasury stock     -      
-
      (644,499 )    
-
      (3,760 )     (644,499 )     3,760      
-
     
-
 
Net loss     -      
-
      -      
-
     
-
      -      
-
      (12,425 )     (12,425 )
Balance at June 30, 2023     4,659     $
-
      5,345,312     $
-
    $ 260,585       60,148     $ (501 )   $ (198,306 )   $ 61,778  

 

   

Redeemable Convertible

Preferred Stock

            Preferred     Additional                 Total  
    Series O     Series P       Common Stock     Stock     Paid-in      Treasury Stock      Accumulated     Stockholders’  
    Shares     Amount     Shares     Amount       Shares     Amount     Shares     Amount     Capital     Shares     Amount     Deficit       Equity
Balance at December 31,  2021     -     $ -       -     $ -         5,275,329     $       -       4,659     $       -      $ 265,633           $ (264 )   $ (163,774 )    $ 101,595  
Issuance of Series O redeemable convertible preferred stock for cash     11,000       11,000                         -       -       -       -       -       -       -       -       -  
Issuance of Series P redeemable convertible preferred stock for cash            
 
      11,000       11,000         -       -       -       -       -       -       -       -       -  
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock     -       (1,504 )     -       (1,505 )       -       -       -       -       -       -       -       -       -  
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock     -       1,504       -       1,505         -       -       -       -       (4,109 )     -       -       -       (4,109 )
 Redemption of Series O Redeemable Convertible Preferred Stock     (11,000 )     (11,000 )     -       -         -       -       -       -       -       -       -       -       -  
 Redemption of Series P Redeemable Convertible Preferred Stock     -       -       (11,000 )     (11,000 )       -       -       -       -       -       -       -       -       -  
Repurchase of treasury stock     -       -       -       -         -       -       -       -       -       242,902       (1,486 )     -       (1,486 )
Stock-based compensation     -       -       -       -         -       -       -       -       105       -       -       -       105  
Cancellation of common stock related to investment in CBM     -       -       -       -         (22,812 )     -       -       -       -       -       -       -       -  
Fractional shares adjusted for reverse split     -       -       -       -         (5,665 )     -       -       -       (26 )     -       -       -       (26 )
Net loss     -       -       -       -         -       -       -       -       -       -       -       (8,612 )     (8,612 )
Balance at June 30, 2022     -     $ -       -     $ -         5,246,852     $ -       4,659     $ -     $ 261,603       242,902     $ (1,750 )   $ (172,386 )   $ 87,467  

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4


 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

 

    Six Months Ended
June 30,
 
    2023     2022  
Cash flows from operating activities            
Net loss   $ (12,425 )   $ (8,612 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Amortization of right-of-use assets     182      
-
 
Depreciation     32      
-
 
Change in fair value of short-term investment    
-
      1,646  
Change in fair value of long-term investment     -       (1,408 )
Stock-based compensation     2,675       105  
Realized loss on marketable securities     487       568  
Unrealized (gain) loss on marketable securities     (514 )     2,299  
Unrealized loss on note receivable     212      
-
 
Changes in operating assets and liabilities:                
Prepaid expenses and other assets     (229 )     153  
Prepaid acquisition cost     301      
-
 
Deposits with clearing broker     (3,532 )    
-
 
Accounts payable and accrued expenses     (428 )     (239 )
Accrued salaries and benefits     (628 )     7  
Accrued commissions     (8 )    
-
 
Lease liabilities     58      
-
 
Other current liabilities     3      
-
 
Notes receivable, at fair value – net interest accrued     (99 )     (377 )
Deposit    
-
      8  
Net cash used in operating activities     (13,913 )     (5,850 )
                 
Cash flows from investing activities                
Purchase of marketable securities     (34,014 )     (27,460 )
Sale of marketable securities     20,494       28,272  
Proceeds from sale of digital currencies    
-
      93  
Purchase of fixed assets     (419 )    
-
 
Acquisition of FPS, net of cash acquired and receivable owed from FPS     (1,112 )    
-
 
Collection of principal on note receivable     502      
-
 
Funds to employee forgivable loan     (100 )    
-
 
Purchase of short-term and long-term investments     (75 )     (14,605 )
Purchase of short-term and long-term promissory notes    
-
      (1,600 )
Net cash used in investing activities     (14,724 )     (15,300 )
                 
Cash flows from financing activities                
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost    
-
      17,891  
Payment for fractional shares    
-
      (26 )
Redemption of Series O and Series P Redeemable Convertible Preferred Stock    
-
      (22,000 )
Purchase of treasury stock     (939 )     (1,486 )
Net cash used in financing activities     (939 )     (5,621 )
                 
Net decrease in cash and cash equivalents and restricted cash     (29,576 )     (26,771 )
Cash and cash equivalents, beginning of period     33,174       65,562  
Cash and cash equivalents, end of period   $ 3,598     $ 38,791  
                 
Non-cash investing and financing activities                
Transfer from short-term investment to marketable securities   $
-
    $ 1,482  
Reclassify from convertible note receivable to notes receivable at fair value   $
-
    $ 2,147  
Promissory convertible note receivable conversion into common shares   $
-
    $ 1,508  
                 
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:                
Net assets acquired, net of cash acquired and receivable owed from FPS   $ 3,112          
Less - Deposit previously transferred in October 2022 to FPS   $ (2,000 )        
Net cash paid   $ 1,112          

 

See accompanying notes to unaudited condensed consolidated financial statements.

5


 

DOMINARI HOLDINGS INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers. 

 

Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass. 

 

Note 2. Liquidity and Capital Resources

 

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

 

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

 

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2022 Annual Report other than those discussed below.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed balance sheet at December 31, 2022, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, these financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

6


 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Results for interim periods are not necessarily indicative of results to be expected for a full year or any future period.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Deposits with clearing broker

 

Deposits with Dominari Securities’ clearing broker consisted of approximately $7.1 million held in money market funds and liquid insured deposits maintained by the Company with its clearing broker as of June 30, 2023.

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the unaudited condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 10 - Leases).

 

Revenue

 

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

7


 

The following provides detailed information on the recognition of the Company’s revenues from contracts with customers:

 

Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the unaudited condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company’s clients are recognized as other income.

 

Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.

 

Recently adopted accounting standards

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This update amends Topic 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in accordance with ASC 606. The Company adopted ASU 2021-08 on January 1, 2023. There was no material impact to the Company’s unaudited condensed consolidated financial statements from the implementation of ASU 2021-08.

 

Effect of new accounting pronouncements not yet adopted

 

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03. 

 

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

 

Effect of new accounting pronouncements to be adopted in future periods

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

 

8


 

Note 4. FPS Acquisition

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the “FPS Acquisition”). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “FPS Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provides for Dominari Financial’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests.  Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”).  The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing (the “Second Closing”) occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate $1.6 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests. 

 

Consideration Transferred

 

The FPS Acquisition was accounted for as a business combination under ASC 805.

 

Under the terms of the FPS Purchase Agreement and subsequent Amendments and Side Letters, 100% of the FPS Membership Interests were acquired for cash consideration of approximately $3.4 million, which reflected the fair value of net assets acquired, plus a $1 purchase price. At March 31, 2023, Dominari Financial had not finalized the purchase accounting related to the fair value of assets acquired in the FPS Acquisition. Pursuant to the Initial Closing and Second Closing, Dominari Financial had wired a total of approximately $3.6 million in cash to the Seller. The purchase price allocation identified net assets of approximately $3.4 million, resulting in a receivable due from the Seller for approximately $0.2 million. The receivable is not included within the consideration transferred as part of the FPS Acquisition but is included within prepaid expenses and other assets within the unaudited condensed consolidated balance sheet as of March 31, 2023.

 

Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately $0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the unaudited condensed consolidated statement of operations.

 

Fair Value of Net Assets Acquired

 

The following table summarizes the fair values of the assets acquired and liabilities assumed of FPS at the date of acquisition:

 

    March 27,  
    2023  
    (Unaudited)  
ASSETS      
Cash and cash equivalents   $ 92  
Deposits with Clearing Broker-Dealer     3,550  
Other receivables     53  
Prepaid and other current assets     89  
Total assets acquired     3,784  
         
Liabilities        
Accrued expenses   $ 273  
Accrued commissions     25  
Wealth management liabilities     62  
Total liabilities assumed     360  
         
Total net assets of FPS Acquisition     3,424  

 

9


 

Dominari Securities reported a net loss of approximately $7.7 million for the three-months ended June 30, 2023. Revenue for the period ended June 30, 2023, was approximately $0.07 million. The net loss was primarily a result of approximately $5.4 million of bonus and employee compensation expense and professional services of approximately $0.9 million. The bonus and compensation expense and professional service fees related to establishing the operations of the broker-dealer and are included in the general and administrative expenses line item within the unaudited condensed consolidated statement of operations.

 

Note 5. Investments in Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and six months ended June 30, 2023 and 2022, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2023     2022     2023     2022  
Realized loss   $ (432 )   $ (344 )   $ (487 )   $ (568 )
Unrealized gain (loss)     643       (1,967 )     514       (2,299 )
Dividend income     188       72       308       131  
Total   $ 400     $ (2,239 )   $ 335     $ (2,736 )

 

Note 6. Short-term investments

 

The following table presents the Company’s short-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

    June 30,
2023
    December 31,
2022
 
Investment in Vicinity Motor Corp.     13       13  
Total     13       13  

 

There was no change in the fair value of the short-term investments for the six months ended June 30, 2023.

 

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

 

    June 30,
2023
    December 31,
2022
 
Option term (in years)     1.3       1.8  
Volatility     76.9 %     76.90 %
Risk-free interest rate     4.47 %     4.47 %
Expected dividends     0.00 %     0.00 %
Stock price   $ 0.96     $ 0.96  

  

10


 

Note 7. Long-Term Investments

 

The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company’s long-term investments as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

    Cost Basis     June 30,
2023
    December  31,
2022
 
Investment in Kerna Health Inc   $ 2,140     $ 4,940     $ 4,940  
Investment in Kaya Now     1,500      
-
     
-
 
Investment in Tevva Motors     1,972       2,794       2,794  
Investment in ASP Isotopes     1,300      
-
     
-
 
Investment in AerocarveUS Corporation     1,075       1,075       1,000  
Investment in Qxpress     1,000       1,000       1,000  
Investment in Masterclass     170       170       170  
Investment in Kraken     597       597       597  
Investment in Epic Games     3,500       3,500       3,500  
Investment in Tesspay     1,240       2,500       2,500  
Investment in SpaceX     3,500       3,674       3,674  
Investment in Databricks     1,200       1,200       1,200  
Investment in Discord     476       476       476  
Investment in Thrasio     300       300       300  
Investment in Automation Anywhere     476       476       476  
Investment in Anduril     476       476       476  
Total   $ 20,922     $ 23,178     $ 23,103  

 

Investment in AerocarveUS Corporation

 

On November 22, 2021, the Company entered into an agreement (the “AerocarveUS Agreement”) with AerocarveUS Corporation, (“AerocarveUS”). Under the AerocarveUS Agreement, the Company agreed to purchase 250,000 shares of common stock of AerocarveUS for $1.0 million. AerocarveUS changed its name to “Unusual Machines, Inc.” on July 5, 2022. In March of 2023, the Company was issued an additional 64,377 shares at no cost. In June 2023, the Company purchased an additional 150,000 shares of common stock for approximately $0.08 million. The investment in AerocarveUS Corporation (a.k.a. Unusual Machines, Inc.) was valued at approximately $1.08 million as of June 30, 2023.

 

Note 8. Notes Receivable

 

The following table presents the Company’s notes receivable as of June 30, 2023 ($ in thousands):

 

    Maturity Date   Stated Interest Rate     Principal Amount     Interest Receivable     Fair Value  
Notes receivable, at fair value                            
Convergent convertible note - current   01/29/2023     8 %   $ 1,000     $ 199     $ 1,199  
Convergent convertible note - non-current   01/29/2023     8 %   $ 500     $
-
    $ 500  
Raefan Industries LLC Investment   12/31/2023     8 %   $ 4,518     $ 623     $ 5,141  
American Innovative Robotics Investment   04/01/2027     8 %   $ 1,100     $ 22     $ 1,122  
                                     
Notes receivable, at fair value - current portion                               $ 6,339  
                                     
Notes receivable, at fair value - non-current portion                               $ 1,622  

 

 

11


 

Convergent Therapeutics, Inc. Investment

 

The Company’s 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of approximately $1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a contractual repayment schedule with the Company. Pursuant to the schedule, Convergent will make a total of eight payments in the amount of $250 thousand and accrued interest, every three months until fully satisfied.

 

The principal balance of the Convergent Convertible Note was approximately $1.8 million as of June 30, 2023. The Company recorded principal repayment of $0.5 million and interest income of approximately $0.1 million on the Convergent Convertible Note for the six months ended June 30, 2023.

 

Raefan Industries LLC Investment

  

The Company recorded an interest income receivable of approximately $0.6 million on the Raefan Industries Promissory Note as of June 30, 2023 and an unrealized loss on the note of approximately $0.2 million.

  

American Innovative Robotics, LLC Investment

  

The Company recorded interest income of approximately $44,000 on the Robotics Promissory Note for the six months ended June 30, 2023.

 

Kaya Now Inc. Investment

 

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya’s business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of $0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a $0 balance for the Kaya Now Promissory Note as of June 30, 2023.

 

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately $10,000 for the six months ended June 30, 2023.

   

Note 9. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

12


 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of June 30, 2023, and December 31, 2022 ($ in thousands):

 

    Fair value measured as of June 30, 2023  
    Total at 
June 30,
    Quoted
prices in
active markets
    Significant other
observable inputs
   

Significant unobservable

inputs

 
    2023     (Level 1)     (Level 2)     (Level 3)  
Assets                        
Marketable securities:                        
Equities   $ 20,675     $ 20,675     $
       -
    $
-
 
Total marketable securities   $ 20,675     $ 20,675     $
-
    $
-
 
Short-term investment   $ 13     $
-
    $
-
    $ 13  
Notes receivable at fair value, current portion   $ 6,339     $
-
    $
-
    $ 6,339  
Notes receivable at fair value, non-current portion   $ 1,622     $
-
    $
-
    $ 1,622  

 

    Fair value measured as of December 31, 2022  
    Total at
December 31,
    Quoted
prices in
active
markets
    Significant other
observable inputs
    Significant
unobservable
inputs
 
    2022     (Level 1)     (Level 2)     (Level 3)  
Assets                        
Marketable securities:                        
Equities   $ 7,130     $ 7,130     $
    -
    $
-
 
Total marketable securities   $ 7,130     $ 7,130     $
-
    $
-
 
Short-term investment   $ 13     $
-
    $
-
    $ 13  
Notes receivable at fair value, current portion   $ 7,474     $
-
    $
-
    $ 7,474  
Notes receivable at fair value, non-current portion   $ 1,100     $
-
    $
-
    $ 1,100  

 

13


 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

  

Short-term investment at December 31, 2022   $ 13  
Short-term investment at June 30, 2023   $ 13  
       
Notes receivable at fair value, current portion at December 31, 2022   $ 7,474  
Collection of principal outstanding     (500 )
Note receivable, Convergent Therapeutics, non-current portion     (500 )
Unrealized loss on note receivable     (212 )
Accrued interest receivable     77  
Notes receivable at fair value, current portion at June 30, 2023   $ 6,339  

 

Notes receivable at fair value, non-current portion at December 31, 2022   $ 1,100  
Note receivable, Convergent Therapeutics, non-current portion     500  
Accrued interest receivable     22  
Notes receivable at fair value, non-current portion at June 30, 2023   $ 1,622  

 

Note Receivable at fair value

   

As of June 30, 2023, the fair value of the notes receivable was measured taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No material change was noted in the fair value of the notes receivable during the three months ended June 30, 2023.

 

Note 10. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

14


 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the Premises in February 2023.

  

The tables below represent the Company’s lease assets and liabilities as of June 30, 2023:

 

    June 30,
2023
 
Assets:        
Operating lease right-of-use-assets   $ 3,530  
         
Liabilities:        
Current        
Operating     353  
Long-term        
Operating     3,259  
    $ 3,612  

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   

June 30,

2023

 
Weighted-average remaining lease term – operating leases (in years)     7.0  
Weighted-average discount rate – operating leases     10.0 %

 

During the six months ended June 30, 2023, the Company recorded approximately $0.4 million of lease expense to current period operations.

 

    Three Months Ended     Six  Months Ended
    June 30,
2023
    June 30,
2023
 
Operating leases            
Operating lease cost   $ 179     $ 313  
Operating lease expense     179       313  
Short-term lease rent expense     33       63  
Net rent expense   $ 212     $ 376  

 

Supplemental cash flow information related to leases were as follows:

 

    Six Months
Ended
 
    June 30,
2023
 
Operating cash flows - operating leases   $ 72  
Right-of-use assets obtained in exchange for operating lease liabilities   $ 2,796  

 

15


 

As of June 30, 2023, future minimum payments during the next five years and thereafter are as follows:

 

    Operating  
    Leases  
Remaining Period Ended December 31, 2023   $ 327  
Year Ended December 31, 2024     750  
Year Ended December 31, 2025     688  
Year Ended December 31, 2026     688  
Year Ended December 31, 2027     688  
Year Ended December 31, 2028     770  
Thereafter     1,166  
Total     5,077  
Less present value discount     (1,465 )
Operating lease liabilities   $ 3,612  

 

Note 11. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the six months ended June 30, 2023, and 2022 are as follows:

 

    As of June 30,  
    2023     2022  
Convertible preferred stock     34       34  
Warrants to purchase common stock     444,796       444,796  
Options to purchase common stock     30,336       198,574  
Total     475,166       643,404  

 

Note 12. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

On March 6, 2023, the Company cancelled 644,499 shares of common stock as a result of retirement of 644,499 shares of treasury stock.

 

On March 20, 2023, the Company cancelled 25,000 shares of common stock owned by a board member.

 

June 27, 2023, pursuant to Soo Yu’s employment agreement and the Company’s 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,033,591 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the shares granted to satisfy Soo Yu’s tax obligation of approximately $1.3 million and recorded as income taxes withheld within the unaudited condensed consolidated balance sheet. See Restricted Stock roll-forward below.

  

16


 

Treasury Stock

 

On January 21, 2022, the Company’s board of directors authorized a share buyback program (the “Share Buyback Program”), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the six months ended June 30, 2023, the Company repurchased 236,630 shares at a cost of approximately $0.9 million or $3.97 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.

 

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately $3.8 million.

 

Warrants

 

A summary of warrant activity for the six months ended June 30, 2023, is presented below:

 

    Warrants     Weighted
Average
Exercise Price
    Total
Intrinsic
Value
    Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2022     444,796     $ 29.25      
   -
      3.20  
Outstanding as of June 30, 2023     444,796     $ 29.25      
-
      2.71  

 

Restricted Stock Awards

 

A summary of restricted stock awards activity for the six months ended June 30, 2023, is presented below:

 

    Number of Restricted
Stock Awards
    Weighted Average
Grant Day Fair Value
 
Nonvested at December 31, 2022     8,068     $ 5.64  
Granted     529,715     $ 2.58  
Vested     (537,783 )     2.63  
Nonvested at June 30, 2023    
-
    $
-
 

 

As of June 30, 2023, there is no unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

A summary of option activity under the Company’s stock option plan for the six months ended June 30, 2023 is presented below:

 

    Number of Shares     Weighted Average
Exercise Price
    Total Intrinsic Value     Weighted Average
Remaining Contractual
Life (in years)
 
Outstanding as of December 31, 2022     31,193     $ 302.97     $
     -
      7.9  
Employee options expired     (857 )   $ 9,719.07                  
Outstanding as of June 30, 2023     30,336     $ 36.97     $
-
      7.6  
Options vested and exercisable     26,578     $ 41.35     $
-
      7.5  

 

Stock-based compensation associated with the amortization of stock option expense was approximately $8,000 and $0 for the six months ended June 30, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $7,000.

 

17


 

Note 13. Revenue

 

The following table presents our total revenues disaggregated by revenue type for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

    Three Months Ended
June 30,
    Six Months Ended
June 30,
 
    2023         2022         2023       2022  
Underwriting   $ 43     $
-
    $ 43     $
-
 
Commissions     14      
-
      14      
-
 
Other     14      
-
    $ 14      
-
 
Total   $ 71     $
-
    $ 71     $
 -
 

 

Note 14. Commitments and Contingencies

 

Legal Proceedings

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

 

Note 15. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of June 30, 2023, Dominari Securities had net capital of approximately $7.3 million, which was approximately $7.2 million in excess of required minimum net capital of $0.1 million.

 

Note 16. Related Party Transaction

 

In 2021, the Company engaged the services of Revere Securities, LLC (“Revere”) to strategically manage and build the Company’s investment processes. Kyle Wool, Board Member, is also a member of the board of directors of Revere. The Company incurred fees of approximately $0.08 million and $0.6 million during the six months ending June 30, 2023, and 2022, respectively. These fees were included in general and administrative expense in the unaudited condensed consolidated statements of operations.

 

18


 

Note 17. Segment Reporting

 

The Company operates in two reportable business segments: (1) Dominari Securities and (2) Legacy AIkido Pharma. The Dominari Securities reportable business segment represents the Company’s broker-dealer business, which is composed of underwriting and transactional service activities. The Legacy AIkido Pharma reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy AIkido Pharma.

 

The chief operating decision-maker (“CODM”) has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies.” While assets are primarily held within the Legacy AIkido Pharma reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

 

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

 

    Three Months Ended June 30, 2023  
    Dominari Securities     Legacy AIkido Pharma     Consolidated  
Revenue   $ 71     $
-  
    $ 71  
Operating Costs                        
General and administrative     6,957       2,123     $ 9,080  
Research and development             2       2  
Loss from operations   $ (6,886 )   $ (2,125 )   $ (9,011 )
                         
Other (expenses) income                        
Other income                    
-  
 
Interest income     44       116       160  
Loss on marketable securities             400       400  
Unrealized loss on note receivable             (212 )     (212 )
Total other (expenses) income   $ 44     $ 304     $ 348  
Net loss   $ (6,842 )   $ (1,821 )   $ (8,663 )

 

    Six Months Ended June 30, 2023  
    Dominari Securities     Legacy AIkido Pharma     Consolidated  
Revenue   $ 71     $ -       $ 71  
Operating Costs                        
General and administrative     8,056       4,857       12,913  
Research and development             3       3  
Loss from operations   $ (7,985 )   $ (4,860 )   $ (12,845 )
                         
Other (expenses) income                        
Other income            
-  
     
-  
 
Interest income     44       253       297  
Loss on marketable securities             335       335  
Unrealized loss on note receivable             (212 )     (212 )
Total other (expenses) income   $ 44     $ 376     $ 420  
Net loss   $ (7,941 )   $ (4,484 )   $ (12,425 )

 

19


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements. All references to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise.

 

Overview

 

Dominari Holdings Inc. (the “Company”), formerly AIkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (Dominari Securities), an introducing broker-dealer, registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.  

 

Additionally, AIkido Labs, LLC (“Aikido Labs”), another wholly owned subsidiary of the Company, is in the process of winding down its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Aikido Labs has historically explored opportunities in high growth industries and has equity holdings including Anduril Industries, Inc, Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass.  

  

Reverse Stock Split

 

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the unaudited condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $26,000.

 

Critical Accounting Policies

 

Our discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements. We have identified the accounting policies that we believe require application of management’s most subjective judgments, often requiring the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Our actual results may differ substantially from these estimates under different assumptions or conditions. There have been no significant changes to our critical accounting policies and estimates since December 31, 2022. The following represent those critical accounting policies that we believe most significantly impact the judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements. 

 

20


 

Long-term investments

 

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

 

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.

 

Refer to Note 3 of the Annual Report for a discussion of all accounting policies.

 

Recently Issued Accounting Pronouncements

 

See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards.  

 

Results of Operations

 

Three Months Ended June 30, 2023, compared to the Three Months Ended June 30, 2022

 

During the three months ended June 30, 2023, we recognized approximately $0.07 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the three months ended June 30, 2023, and 2022, we incurred a loss from operations of approximately $9.0 million and $2.3 million, respectively. The consistent loss in operations year over year was primarily attributable to the following:

 

  i. An approximate $6.8 million increase in general and administrative expenses – driven by approximately $0.02 million and $0.8 million of professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the Company also incurred increased compensation expenses of approximately $6.3 million due to growing operations.

 

  ii. An approximate $0.03 million decrease in research and development expenses – attributable to the Company’s strategic business decision to transition away from the biotechnology industry and into financial services. The result is a decrease in research and development related expenses by almost 100%.

 

During the three months ended June 30, 2023 and 2022, other income (expenses) was approximately $0.3 million and $(2.8) million, respectively. The activity for the three months ended June 30, 2023 and 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of short and long-term investments. Specifically:

 

  i. Marketable securities – we recognized a gain of approximately $0.4 million for the three months ended June 30, 2023. The decrease of approximately $2.6 million in losses over prior year is a direct result of a decrease in unrealized losses of approximately $2.6 million and increase in dividend income of approximately $0.1 million, offset by an increase in realized loss of approximately $0.08 million. The decreases were driven by both market improvement and decrease in sale activity resulting in fewer realized losses.

 

  ii. Short-term and long-term investments –The changes over the three months ended June 30, 2023 and 2022 are a function of observable market transactions which resulted in a decrease in unrealized loss of approximately $0.8 million on the adjusted fair value of the investments during the three months ended June 30, 2023 and 2022, respectively.

 

21


 

Six Months Ended June 30, 2023, compared to the Six months ended June 30, 2022

 

During the six months ended June 30, 2023, we recognized approximately $0.07 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the six months ended June 30, 2023, and 2022, we incurred a loss from operations of approximately $12.8 million and $6.1 million, respectively. The consistent loss in operations year over year was primarily attributable to the following:

 

  i. An approximate $8.9 million increase in general and administrative expenses – driven by approximately $0.1 million and $0.9 million of professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the Company also incurred increased compensation expenses of approximately $6.3 million due to growing operations.

 

  ii. An approximate $2.0 million decrease in research and development expenses – attributable to the Company’s strategic business decision to transition away from the biotechnology industry and into financial services. The result is a decrease in research and development related expenses by almost 100%.

 

During the six months ended June 30, 2023 and 2022, other income (expenses) was approximately $0.4 million and $(2.5) million, respectively. The activity for the six months ended June 30, 2023 and 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of short and long-term investments. Specifically:

 

  i. Marketable securities – we recognized a gain of approximately $0.3 million for the six months ended June 30, 2023. The decrease of approximately $3.1 million in losses over prior year is a direct result of a decrease in unrealized losses of approximately $2.8 million and increase in dividend income of approximately $0.2 million, offset by an increase in realized loss of approximately $0.08 million. The decreases were driven by both market improvement and decrease in sale activity resulting in fewer realized losses.

 

  ii. Short-term and long-term investments –The changes over the six months ended June 30, 2023 and 2022 are a function of observable market transactions which resulted in a decrease in unrealized loss of approximately $0.2 million on the adjusted fair value of the investments during the six months ended June 30, 2023 and 2022, respectively.

 

Liquidity and Capital Resources

 

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

 

  managing current cash and cash equivalents on hand from our past debt and equity offerings;

 

  seeking additional funds raised through the sale of additional securities in the future; and

 

  seeking additional liquidity through credit facilities or other debt arrangements.

 

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately $35.7 million as of June 30, 2023. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital, and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly-traded company or from continuing operations.

 

22


 

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

 

Cash Flows from Operating Activities

 

For the six months ended June 30, 2023 and 2022, net cash used in operations was approximately $13.9 million and $5.9 million, respectively. The cash used in operating activities for the six months ended June 30, 2023, is primarily attributable to a net loss of approximately $11.7 million, approximately $0.5 million of realized gain on marketable securities and changes in operating assets and liabilities of $4.6 million, partially offset by $2.7 million stock-based compensation expense and approximately $0.5 million in unrealized losses on marketable securities. The cash used in operating activities for the three months ended June 30, 2022 primarily resulted from a net loss of $8.6 million and change in fair value of long-term investment of $1.4 million and is partially offset by change in fair value of short-term investment of $1.6 million and unrealized loss on marketable securities of $2.3 million. 

 

Cash Flows from Investing Activities

 

For the six months ended June 30, 2023 and 2022, net cash used in investing activities was approximately $14.7 million and $15.3 million, respectively. The cash used in investing activities for the six months ended June 30, 2023, primarily resulted from our purchase of marketable securities of approximately $34.0 million and the acquisition of FPS of approximately $1.1 million, partially offset by our sale of marketable securities of approximately $20.5 million. The Company also collected approximately $0.5 million in principal related to its short-term notes. The cash used in investing activities for the six months ended June 30, 2022 primarily resulted from our purchase of marketable securities of $27.5 million, purchase of promissory notes of $1.6 million and purchase of investments of $14.6 million, partially offset by our sale of marketable securities of $28.3 million since we invest excess cash into marketable securities until additional cash is needed.

 

Cash Flows from Financing Activities

 

For the six months ended June 30, 2023, cash used in financing activities was approximately $0.9 million, which reflects the cost for purchase of treasury stock of approximately $0.9 million. Cash used in financing activities for the six months ended June 30, 2022 was $5.6 million, which reflects the cost for redemption of Series O and Series P Redeemable Convertible Preferred Stock of $22.0 million and cost for purchase of treasury stock of $1.5 million, partially offset by net proceeds of $17.9 million from investors in exchange of issuance of issuance of Series O and Series P Redeemable Convertible Preferred Stock. 

 

23


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

During the quarter ended June 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective, as of the end of the period covered by this report.

  

Changes in Internal Control Over Financial Reporting

 

We have not made any changes to our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 

 

Limitations on Effectiveness of Controls

 

Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

24


  

Part II. Other Information

 

Item 1. Legal Proceedings

 

In the past, in the ordinary course of business, we actively pursued legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. Other than ordinary routine litigation incidental to the business, we know of no material, active or pending legal proceedings against us.

 

Item 1A. Risk Factors

 

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q and in the other periodic and current reports and other documents we file with the Securities and Exchange Commission, including but not limited to our annual report on Form 10-K for the fiscal year ended December 31, 2022, before deciding to invest in our common stock. If any of the following risks materialize, our business, financial condition, results of operation and future prospects will likely be materially and adversely affected. In that event, the market price of our common stock could decline and you could lose all or part of your investment. This list is not exhaustive and the order of presentation does not reflect management’s determination of priority or likelihood. 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits

 

10.1   Employment Agreement, made and entered into as of April 3, 20234, by and between Dominari Securities LLC and Soo Yu filed with the Securities and Exchange Commission on May 11, 2023, as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023
10.2   Amendment to Employment Agreement, made and entered into as of April 19, 2023, by and between Dominari Securities LLC and Soo Yu filed with the Securities and Exchange Commission on May 11, 2023, as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023
31.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith

 

25


 

Signatures

 

Pursuant to the requirements of the Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  DOMINARI HOLDINGS INC.
     
Date: August 9, 2023 By: /s/ Anthony Hayes
    Anthony Hayes
    Chief Executive Officer
    (Principal Executive Officer)

 

     
Date: August 9, 2023 By: /s/ George Way
    George Way
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

26

 

 

1.18 1.79 2.42 2.45 4827239 5065055 5251023 5251766 false --12-31 Q2 0000012239 0000012239 2023-01-01 2023-06-30 0000012239 2023-08-08 0000012239 2023-06-30 0000012239 2022-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2023-06-30 0000012239 us-gaap:SeriesDPreferredStockMember 2022-12-31 0000012239 domh:SeriesD1PreferredStockMember 2023-06-30 0000012239 domh:SeriesD1PreferredStockMember 2022-12-31 0000012239 2023-04-01 2023-06-30 0000012239 2022-04-01 2022-06-30 0000012239 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2023-03-31 0000012239 us-gaap:CommonStockMember 2023-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2023-03-31 0000012239 us-gaap:RetainedEarningsMember 2023-03-31 0000012239 2023-03-31 0000012239 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000012239 us-gaap:PreferredStockMember 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-03-31 0000012239 us-gaap:CommonStockMember 2022-03-31 0000012239 us-gaap:PreferredStockMember 2022-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-03-31 0000012239 us-gaap:RetainedEarningsMember 2022-03-31 0000012239 2022-03-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-06-30 0000012239 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-12-31 0000012239 us-gaap:CommonStockMember 2022-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012239 us-gaap:RetainedEarningsMember 2022-12-31 0000012239 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0000012239 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2021-12-31 0000012239 us-gaap:CommonStockMember 2021-12-31 0000012239 us-gaap:PreferredStockMember 2021-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2021-12-31 0000012239 us-gaap:RetainedEarningsMember 2021-12-31 0000012239 2021-12-31 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesORedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:PreferredStockMember 2022-01-01 2022-06-30 0000012239 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0000012239 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0000012239 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0000012239 us-gaap:RedeemableConvertiblePreferredStockMember domh:SeriesPRedeemableConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 domh:FPSPurchaseAgreementMember 2022-10-01 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2023-01-01 2023-06-30 0000012239 domh:FPSPurchaseAgreementMember 2023-06-30 0000012239 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-03-27 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 domh:InvestmentInVicinityMotorCorpMember 2023-06-30 0000012239 domh:InvestmentInVicinityMotorCorpMember 2022-12-31 0000012239 domh:VicinityMotorCorpMember 2023-01-01 2023-06-30 0000012239 domh:VicinityMotorCorpMember 2022-01-01 2022-12-31 0000012239 2021-11-22 2021-11-22 0000012239 2023-03-01 2023-03-31 0000012239 2023-06-01 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2023-06-30 0000012239 domh:InvestmentInKernaHealthIncMember 2022-12-31 0000012239 domh:InvestmentInKayaNowMember 2023-06-30 0000012239 domh:InvestmentInKayaNowMember 2022-12-31 0000012239 domh:InvestmentInTevvaMotorsMember 2023-06-30 0000012239 domh:InvestmentInTevvaMotorsMember 2022-12-31 0000012239 domh:InvestmentInASPIsotopesMember 2023-06-30 0000012239 domh:InvestmentInASPIsotopesMember 2022-12-31 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2023-06-30 0000012239 domh:InvestmentInAerocarveUSCorporationMember 2022-12-31 0000012239 domh:InvestmentInQxpressMember 2023-06-30 0000012239 domh:InvestmentInQxpressMember 2022-12-31 0000012239 domh:InvestmentInMasterclassMember 2023-06-30 0000012239 domh:InvestmentInMasterclassMember 2022-12-31 0000012239 domh:InvestmentInKrakenMember 2023-06-30 0000012239 domh:InvestmentInKrakenMember 2022-12-31 0000012239 domh:InvestmentInEpicGamesMember 2023-06-30 0000012239 domh:InvestmentInEpicGamesMember 2022-12-31 0000012239 domh:InvestmentInTesspayMember 2023-06-30 0000012239 domh:InvestmentInTesspayMember 2022-12-31 0000012239 domh:InvestmentInSpaceXMember 2023-06-30 0000012239 domh:InvestmentInSpaceXMember 2022-12-31 0000012239 domh:InvestmentInDatabricksMember 2023-06-30 0000012239 domh:InvestmentInDatabricksMember 2022-12-31 0000012239 domh:InvestmentInDiscordMember 2023-06-30 0000012239 domh:InvestmentInDiscordMember 2022-12-31 0000012239 domh:InvestmentInThrasioMember 2023-06-30 0000012239 domh:InvestmentInThrasioMember 2022-12-31 0000012239 domh:InvestmentInAutomationAnywhereMember 2023-06-30 0000012239 domh:InvestmentInAutomationAnywhereMember 2022-12-31 0000012239 domh:InvestmentInAndurilMember 2023-06-30 0000012239 domh:InvestmentInAndurilMember 2022-12-31 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 us-gaap:NotesPayableOtherPayablesMember domh:ConvergentTherapeuticsIncInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-06-30 0000012239 domh:RaefanIndustriesLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsLLCInvestmentMember 2022-01-01 2022-12-31 0000012239 domh:KayaNowPromissoryNoteMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteCurrentPortionMember 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-01-01 2023-06-30 0000012239 domh:ConvergentConvertibleNoteNoncurrentPortionMember 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-01-01 2023-06-30 0000012239 domh:AmericanInnovativeRoboticsInvestmentMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueCurrentPortionMember 2023-06-30 0000012239 domh:NotesReceivableAtFairvalueNoncurrentPortionMember 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel2Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel3Member 2023-06-30 0000012239 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0000012239 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 domh:OperatingLeaseMember 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-06-30 0000012239 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 us-gaap:WarrantMember 2022-01-01 2022-06-30 0000012239 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0000012239 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0000012239 2023-03-06 0000012239 2023-03-20 0000012239 us-gaap:CommonStockMember 2023-06-01 2023-06-27 0000012239 2023-06-01 2023-06-27 0000012239 2022-01-01 2022-01-21 0000012239 2023-03-01 2023-03-06 0000012239 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-06-30 0000012239 us-gaap:OverAllotmentOptionMember 2022-01-01 2022-06-30 0000012239 us-gaap:WarrantMember 2021-12-31 0000012239 us-gaap:WarrantMember 2022-12-31 0000012239 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000012239 us-gaap:WarrantMember 2023-06-30 0000012239 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-04-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-04-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-04-01 2023-06-30 0000012239 domh:DominariSecuritiesMember 2023-01-01 2023-06-30 0000012239 domh:ConsolidatedMember 2023-01-01 2023-06-30 0000012239 domh:LegacyAIkidoPharmaMember 2023-01-01 2023-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0623ex31-1_dominari.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Anthony Hayes, certify that:

  1. I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

 

 2.

 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2023  
   
  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)

 

 

EX-31.2 3 f10q0623ex31-2_dominari.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, George Way, certify that:

  1. I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

  4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2023  
  /s/ George Way
  George Way
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

EX-32.1 4 f10q0623ex32-1_dominari.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Haynes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

  1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

 
Date: August 9, 2023  
   
  /s/ Anthony Haynes
  Anthony Haynes
  Chief Executive Officer
  (Principal Executive Officer)
EX-32.2 5 f10q0623ex32-2_dominari.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF DOMINARI HOLDINGS INC. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, George Way, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

  1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

 

 
Date: August 9, 2023  
   
  /s/ George Way
  George Way
  Chief Financial Officer
  (Principal Financial and Accounting Officer)